Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis

The aim of this study was to see the correlation between hepatic steatosis inchronic HCV infection and HCV genotypes. Study Design: It was a prospective observationalstudy done. Setting: Isra University Hospital and histopathology laboratory. Period: May toNovember 2014. Material & Methods: The study was conducted on 87 liver biopsy specimensof patients infected with chronic HCV. The biopsy samples were collected from department ofPathology, Isra University. H&E stained sections of liver biopsies were evaluated to determineGrade and Stage of chronic hepatitis C and grade of steatosis. Blood samples of those patientswere collected from Isra University hospital and Asian Institute of Medical Sciences (AIMS),Hyderabad to determine the HCV genotype, platelet count and liver function test including ALT,AST and GGT. Results: It was found that majority of the patients 38 (43.6%) had genotype 3ainfection followed by 3b, 1a, 1b and Un-typeable genotypes. Hepatic steatosis was divided intocategories according to Brunt’s classification. It was found that 39 (44.8%) patients had grade0 steatosis while 48 out of 87 patients presented with steatosis. It was found that 29 (33%)presented with grade 1 steatosis followed by grade 2 and 3. Steatosis was most frequentlyseen with genotype 3a (26.4%) and presented with mild to moderate grade. Conclusions: Thepresent study concludes that hepatic steatosis is more frequent in genotype 3a and presentswith mild to moderate grade.

Download Full-text

Liver steatosis in chronic hepatitis C: A morphological sign suggesting infection with HCV genotype 3

Journal of Hepatology ◽

10.1016/s0168-8278(01)80579-1 ◽

2001 ◽

Vol 34 (0) ◽

pp. 158-159

Author(s):

L Rubbia-Brandt

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Liver Steatosis ◽

Genotype 3 ◽

Hcv Genotype ◽

Morphological Sign ◽

Hcv Genotype 3

Download Full-text

Non-structural 5A (NS5A) protein and HCV genotype 3a sensitivity to interferon (IFN)-alpha therapy

Journal of Hepatology ◽

10.1016/s0168-8278(01)80422-0 ◽

2001 ◽

Vol 34 (0) ◽

pp. 117

Author(s):

L Castera

Keyword(s):

Hcv Genotype ◽

Ns5a Protein ◽

Ifn Alpha ◽

Alpha Therapy ◽

Genotype 3A

Download Full-text

Genotype CC of rs12979860 is providing protection against infection rather than assisting in treatment response for HCV genotype 3a infection

Genes and Immunity ◽

10.1038/gene.2014.31 ◽

2014 ◽

Vol 15 (6) ◽

pp. 430-432 ◽

Cited By ~ 6

Author(s):

A H Hashmi ◽

N Ahmad ◽

S Riaz ◽

L Ali ◽

S Siddiqi ◽

...

Keyword(s):

Treatment Response ◽

Hcv Genotype ◽

Protection Against Infection ◽

Genotype 3A

Download Full-text

The hepatitis C virus NS5A protein and response to interferon α: mutational analyses in patients with chronic HCV genotype 3a infection from India

Medical Microbiology and Immunology ◽

10.1007/s00430-006-0024-z ◽

2006 ◽

Vol 196 (1) ◽

pp. 11-21 ◽

Cited By ~ 7

Author(s):

Ankur Goyal ◽

Wolf P. Hofmann ◽

Eva Hermann ◽

Stella Traver ◽

Syed S. Hissar ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Interferon Α ◽

Hcv Genotype ◽

Ns5a Protein ◽

Chronic Hcv ◽

Genotype 3A

Download Full-text

Why and How to Treat Chronic Hepatitis C

Canadian Journal of Gastroenterology ◽

10.1155/2000/787892 ◽

2000 ◽

Vol 14 (suppl b) ◽

pp. 45B-48B ◽

Cited By ~ 3

Author(s):

Stephanos J Hadziyannis

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Combination Therapy ◽

Chronic Hepatitis C ◽

Cost Effective ◽

Genotype 1 ◽

Related Factors ◽

Major Health Problem ◽

Hcv Genotype ◽

End Stage

Chronic hepatitis C (CHC) is a major health problem worldwide, with approximately 200 million affected individuals and a significant rate of progression to end-stage cirrhosis and hepatocellular carcinoma (HCC). If hepatitis C virus (HCV) infection is left untreated in the population, then the number of liver-related deaths will soon double and the need for liver transplantation may increase to five times that seen today. Available therapies for CHC are restricted to interferon alpha (IFN-α ) monotherapy and to the combination of IFN-α and ribavirin. Despite their high cost and side effects, both of these therapies have proved to be cost effective, particularly combination therapy. IFN-α monotherapy for one year can induce sustained response (SR) rates of approximately 10% in naive patients infected with HCV genotype 1, and above 50% in those infected with other genotypes. Combination therapy can double or even triple the rate of SR in genotype 1 infections and may further increase the SR rate in the other HCV genotypes. Combination therapy has also been proven to be effective in approximately 50% of relapsed responders to IFN-α monotherapy. In clinical practice, the decision to treat should be individualized and tailored on the basis of several virus- and host-related factors, particularly the grade and stage of liver disease, HCV genotype and levels of viremia. Appropriate monitoring of therapy by careful clinical evaluation, liver biochemistry and serumHCVRNAtesting is mandatory. IFN-α therapy may also prove to be effective in reducing the rate of HCC development in CHC regardless of whether a virological response is achieved, but this remains to be established.

Download Full-text

Study of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani population

Virology Journal ◽

10.1186/1743-422x-10-352 ◽

2013 ◽

Vol 10 (1) ◽

Cited By ~ 2

Author(s):

Atika Mansoor ◽

Lubna Ali ◽

Noor-ul Sabah ◽

Asraf Hussain Hashmi ◽

Mohammad Haroon Khan ◽

...

Keyword(s):

Interferon Therapy ◽

Pakistani Population ◽

Hcv Genotype ◽

Genotype 3A

Download Full-text

Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype

European Journal of Gastroenterology & Hepatology ◽

10.1097/00042737-200105000-00007 ◽

2001 ◽

Vol 13 (5) ◽

pp. 501-506 ◽

Cited By ~ 19

Author(s):

Luigi Roffi ◽

Alessandro Redaelli ◽

Guido Colloredo ◽

Eliseo Minola ◽

Carlo Donada ◽

...

Keyword(s):

Chronic Hepatitis ◽

Liver Disease ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Large Cohort ◽

Hcv Genotype

Download Full-text

Distribution of hepatitis C virus genotypes and subtypes in a group of patients with chronic hepatitis C from Canton Sarajevo, 2012-2018

Acta Medica Saliniana ◽

10.5457/ams.v49i0.524 ◽

2019 ◽

Vol 49 ◽

Author(s):

Irma Salimović- Bešić ◽

Adna Kahriman ◽

Suzana Arapčić ◽

Amela Dedeić- Ljubović

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Hcv Rna ◽

Genotype 3 ◽

Hcv Genotype ◽

Hcv Genotypes ◽

Number Of Patients ◽

Subtype 1B

Background: Hepatitis C virus (HCV) genotypes and subtypes exhibit significant geographic variations.Aim: To analyse the distribution of genotypes/subtypes of HCV in a group of patients with chronic hepatitis C from Canton Sarajevo during 2012-2018.Material and methods:The study enrolled 247 human plasma samples of HCV-RNA positive patients with available results of HCV genotyping test.Results: During 2012-2018, the domination of subtypes 1a (34.01%), 1b (28.34%) and genotype 3 (23.89%) was registered. In 2012 and 2013, HCV subtype 1a was the most common (27/63; 42.86% and 17/40; 42.50%, respectively). In 2014, the leading HCV genotype/subtype were 3 and 1b (17/57; 29.82%). In 2015, the dominance of HCV genotype 3 (14/39; 35.90%) continued, while in 2016, the same number of HCV subtypes 1a and 1b (11/30; 36.67%) was recorded. Although in a small number of tested, during 2017, HCV subtype 1b was the most prevalent (7/14; 50.00%), and in 2018, it was replaced by a HCV subtype 1a (3/4; 75.00%). Distribution of HCV genotypes/subtypes by age group of patients varied significantly (p=0.000). The largest number of patients (71/247; 28.74%) belonged to the age category 30-39 years and HCV genotypes/subtypes 1, 3, 4, 1a and 1b were identified. Except in 2017, male gender significantly dominated (p=0.000). In males, HCV subtype 1a (68/170; 40.00%) was the most common, while in women it was HCV subtype 1b (44/77; 57.14%).Conclusion: This six-year retrospective study showed the time variations of the circulating HCV genotypes/subtypes among patients with chronic hepatitis C in Canton Sarajevo. Genotyping of the HCV has an important implications for diagnosis and treatment of the patients.

Download Full-text